Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (361-370 of 600) with videos related to

Pageof 60
Sort By:
Rheumatology (Oxford, England)|October 31, 2019
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA studyCarmen Stolwijk, Ivette Essers, Filip van den Bosch, et al.
Arthritis Care & Research|April 28, 2020
Patient Global Assessment of Disease Activity and Radiographic Progression in Early Arthritis: Three-Year Results From the ESPOIR CohortRicardo J O Ferreira, Bruno Fautrel, Alain Saraux, et al.
Joint Bone Spine|February 7, 2018
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritisDaniel Wendling, Cédric Lukas, Clément Prati, et al.
RMD Open|January 31, 2025
Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA studyRodolfo Perez-Alamino, Hernan Maldonado-Ficco, Anna Moltó, et al.
Arthritis and Rheumatism|May 29, 2007
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitisWalter P Maksymowych, Robert Landewé, Barbara Conner-Spady, et al.
The New England Journal of Medicine|December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisDominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|August 30, 2014
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY studyT W J Huizinga, Philip G Conaghan, Emilio Martin-Mola, et al.
Rheumatology (Oxford, England)|November 20, 2013
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitisCarmen Stolwijk, Astrid van Tubergen, Sofia Ramiro, et al.
RMD Open|February 6, 2021
Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patientsCatia Duarte, Eduardo José Ferreira Santos, Ricardo J O Ferreira, et al.
The Journal of Rheumatology|December 17, 2003
Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritisBernard Combe, Alain Cantagrel, Philippe Goupille, et al.
Pageof 60

Showing results (361-370 of 600) with videos related to

Sort By:
Pageof 60
Rheumatology (Oxford, England)|October 31, 2019
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA studyCarmen Stolwijk, Ivette Essers, Filip van den Bosch, et al.
Arthritis Care & Research|April 28, 2020
Patient Global Assessment of Disease Activity and Radiographic Progression in Early Arthritis: Three-Year Results From the ESPOIR CohortRicardo J O Ferreira, Bruno Fautrel, Alain Saraux, et al.
Joint Bone Spine|February 7, 2018
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritisDaniel Wendling, Cédric Lukas, Clément Prati, et al.
RMD Open|January 31, 2025
Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA studyRodolfo Perez-Alamino, Hernan Maldonado-Ficco, Anna Moltó, et al.
Arthritis and Rheumatism|May 29, 2007
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitisWalter P Maksymowych, Robert Landewé, Barbara Conner-Spady, et al.
The New England Journal of Medicine|December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisDominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|August 30, 2014
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY studyT W J Huizinga, Philip G Conaghan, Emilio Martin-Mola, et al.
Rheumatology (Oxford, England)|November 20, 2013
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitisCarmen Stolwijk, Astrid van Tubergen, Sofia Ramiro, et al.
RMD Open|February 6, 2021
Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patientsCatia Duarte, Eduardo José Ferreira Santos, Ricardo J O Ferreira, et al.
The Journal of Rheumatology|December 17, 2003
Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritisBernard Combe, Alain Cantagrel, Philippe Goupille, et al.
Pageof 60